ArticleFood science & nutrition2025
Evaluation of the Effects of Chitin and Chitosan on Pseudo-Allergic Reaction by Inhibiting MRGPRX2 Activation.
Article in Food science & nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Novel Chitosan Bioink Derived fromACS omega · 2026Article
- Article
- Evaluation of the Effects of Chitin and Chitosan on Pseudo-Allergic Reaction by Inhibiting MRGPRX2 Activation.Food science & nutrition · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chitin and chitosan, characterized by their extensive applications, abundant availability, and low cost, have been demonstrated to modulate immune responses. Mast cells (MCs) are important innate immune cells, and few studies on the regulation of MCs by chitin and chitosan were conducted. The key receptor Mas-related G protein-coupled receptor X2 (MRGPRX2), highly expressed in MCs, is involved in drug pseudo-allergic responses and several chronic diseases by mediating MC activation. However, the inhibitory effects of chitin and chitosan on MRGPRX2 activation of MCs have not been reported. To verify whether chitin and chitosan inhibit MRGPRX2-mediated MCs activation and determine which of these compounds shows the best inhibitory effect, in vitro MC degranulation reaction and in vivo substance P (SP)-induced local passive anaphylaxis models were used to evaluate the inhibitory effect of chitin and chitosan on MRGPRX2 activation of MCs. We showed that both chitin and chitosan inhibited MC degranulation mediated by MRGPRX2 and reduced β-hexosaminidase, histamine, TNF-α, MCP-1, and IL-8 release in vitro. Chitin and chitosan inhibit local pseudo-allergic reactions and reduce microvascular dilation by inhibiting MRGPRX2-mediated MC activation. Both chitin and chitosan inhibited MRGPRX2-mediated MC degranulation. However, chitosan showed a stronger inhibitory effect. Chitosan has the potential to be incorporated into functional foods as an auxiliary in the treatment of MRGPRX2-mediated chronic diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.